No annual revenue total was found in KAIROS PHARMA, LTD.'s SEC filings.
Kairos Pharma, Ltd. (KAPA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-5.80M
Operating cash flow (TTM)
$-3.97M
Free cash flow
—
EPS (TTM)
$-0.28
Dividend per share
None
Shares outstanding
21.41M
+4.7% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KAPA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1962011
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Operating income | -$5.6M | -$2.3M |
| Net income | -$5.4M | -$2.6M |
| Diluted EPS | -$0.30 | -$0.23 |
| Operating cash flow | -$3.4M | -$4.0M |
| Total assets | $6.5M | $5.8M |
| Total liabilities | — | $992,000 |
| Stockholders' equity | $6.3M | $4.8M |
| Cash and investments | $4.5M | $1.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Nov 3, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 21, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
All 125 Kairos Pharma, Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.